Brokerages predict that Gilead Sciences, Inc. (NASDAQ:GILD) will announce earnings of $1.68 per share for the current quarter, Zacks reports. Eight analysts have issued estimates for Gilead Sciences’ earnings. The lowest EPS estimate is $1.50 and the highest is $1.79. Gilead Sciences posted earnings per share of $1.44 in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.7%. The company is scheduled to report its next quarterly earnings results after the market closes on Tuesday, February 4th.

On average, analysts expect that Gilead Sciences will report full-year earnings of $7.00 per share for the current year, with EPS estimates ranging from $6.83 to $7.13. For the next fiscal year, analysts forecast that the business will report earnings of $7.06 per share, with EPS estimates ranging from $6.50 to $7.80. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same period in the previous year, the firm posted $1.84 EPS. Gilead Sciences’s revenue was up .1% on a year-over-year basis.

GILD has been the subject of several analyst reports. Wells Fargo & Co set a $81.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 25th. Credit Suisse Group downgraded Gilead Sciences from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $67.00 to $63.00 in a research report on Friday, December 13th. Bank of America started coverage on Gilead Sciences in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $70.00 price target on the stock. Oppenheimer upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating in a report on Friday, January 3rd. Finally, SunTrust Banks began coverage on shares of Gilead Sciences in a research note on Tuesday, November 12th. They set a “hold” rating and a $70.00 price objective for the company. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences presently has an average rating of “Hold” and a consensus price target of $78.91.

In related news, EVP Brett A. Pletcher sold 2,950 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $64.63, for a total value of $190,658.50. Following the completion of the sale, the executive vice president now directly owns 20,014 shares in the company, valued at approximately $1,293,504.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 5,677 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $63.31, for a total value of $359,410.87. Following the completion of the sale, the executive vice president now owns 21,521 shares of the company’s stock, valued at $1,362,494.51. The disclosure for this sale can be found here. Insiders sold 45,622 shares of company stock worth $2,986,438 in the last 90 days. 0.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of GILD. First Financial Corp IN grew its position in Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 401 shares in the last quarter. M&R Capital Management Inc. boosted its stake in shares of Gilead Sciences by 83.3% in the fourth quarter. M&R Capital Management Inc. now owns 550 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 250 shares during the period. Venturi Wealth Management LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at $40,000. Front Row Advisors LLC grew its holdings in Gilead Sciences by 286.0% during the 2nd quarter. Front Row Advisors LLC now owns 691 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 512 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in Gilead Sciences by 30.7% during the 3rd quarter. Larson Financial Group LLC now owns 826 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 194 shares during the period. 79.27% of the stock is owned by institutional investors.

Shares of GILD stock traded down $0.32 during mid-day trading on Monday, hitting $63.11. 4,369,011 shares of the company’s stock were exchanged, compared to its average volume of 6,223,007. Gilead Sciences has a fifty-two week low of $60.89 and a fifty-two week high of $70.50. The stock has a 50-day simple moving average of $65.50 and a two-hundred day simple moving average of $65.07. The company has a quick ratio of 2.87, a current ratio of 2.96 and a debt-to-equity ratio of 1.11. The stock has a market cap of $79.89 billion, a price-to-earnings ratio of 30.20, a PEG ratio of 3.81 and a beta of 1.11.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.